Journals / Veterinary Sciences and Practices / 2017 / Cilt: 12 Sayı: 2

Effects of L-Carnitine and Co-enzyme Q10 Together with ACE Inhibitors on Total Oxidant and Antioxidant Levels in L-Name Hypertensive Rats

L-Name Hipertansif Ratlarda Ace İnhibitörü ile Birlikte L-Karnitin ve Co-enzim Q10 Verilmesinin Total Oksidan ve Antioksidan Düzeyleri Üzerine Etkileri

Pages
143–151
Publication Date
2017-10-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was concluded that due to the antioxidant properties of L-carnitine and Co-enzyme Q10 in hypertension, these substances protects the heart and vascular system against free-radical damage, and also reducing the severity of secondary problems.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study we aimed to find out the affects of giving ACE inhibitor with L-carnitine and Co-enzyme Q10 on the oxidant-antioxidant system.
📊
Key Findings & Data:For this purpose, 8 week-old and approximately 200-250 gr, 60 adult Sprague-Dawley rats were used.
💡
Conclusion & Impact:It was concluded that due to the antioxidant properties of L-carnitine and Co-enzyme Q10 in hypertension, these substances protects the heart and vascular system against free-radical damage, and also reducing the severity of secondary problems.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:ACE inhibitörü · Antioksidan · Co-enzim Q10

Abstract

In this study we aimed to find out the affects of giving ACE inhibitor with L-carnitine and Co-enzyme Q10 on the oxidant-antioxidant system. For this purpose, 8 week-old and approximately 200-250 gr, 60 adult Sprague-Dawley rats were used. The animal were divided into three groups, served as 1 control and 2 experimental groups and each had 20 rats. Before starting the study, 75 mg/kg L-NAME given intraperitonelly to all groups for ten days to create hypertension. 10 mg/kg ACE inhibitor to the control group, 100 mg/kg L-carnitine+10 mg/kg ACE inhibitor to the L-carnitine group, 100 mg/kg Co-enzyme Q10+10 mg/kg ACE inhibitor to the Co-enzyme Q10 group was given. There were statistically significant decrease in the plasma levels of total oxidant in Co-enzyme Q10 and L-carnitine groups when compared to the control on 28th day (P<0.05). There were no statistically significant difference between the groups in terms of plasma total antioxidant levels. Total oxidant levels of heart tissue in the L-carnitine group was statistically lower than the control group (P<0.001) on the day 14th. There were no statistically significant difference on the total oxidant levels of heart tissue in Co-enzyme Q10 group.The total oxidant levels of heart tissue of the experimental groups were statistically lower than the control group on 28th day, and this decrease was more prominent in the L-carnitine group (P <0.001). There were no statistically significant difference in total antioxidant levels of heart tissue. It was concluded that due to the antioxidant properties of L-carnitine and Co-enzyme Q10 in hypertension, these substances protects the heart and vascular system against free-radical damage, and also reducing the severity of secondary problems.

Özet

Bu çalışma ile L-NAME hipertansif ratlarda ACE inhibitörü ile birlikte L- karnitin ve Co-enzim Q10 verilmesinin total oksidan-antioksidan sistem üzerine etkilerinin araştırılması amaçlandı. Bu amaçla, ortalama 200-250 gr, 8 haftalık, 60 erişkin Spraque-Dawley rat kullanıldı. Ratlar her grupta 20 rat bulunacak şekilde, 1 kontrol ve 2 deney grubu olmak üzere 3 gruba ayrıldı. Çalışmaya başlamadan önce tüm gruplara 10 gün süreyle intraperitonel (i.p) olarak 75 mg/kg L- NAME verilerek hipertansiyon oluşturuldu. Hipertansiyon oluşturulduktan sonra, Kontrol grubuna 10 mg/kg ACE inhibitörü, L-karnitin grubuna 10 mg/kg ACE inhibitörü + 100 mg/kg L-karnitin, Co-enzim Q10 grubuna 10 mg/kg ACE inhibitörü + 100 mg/kg Co-enzim Q10 ip olarak verildi. Plazma total oksidan düzeylerinin hem L-karnitin hem de Co-enzim Q10 gruplarında, kontrol grubuna göre 28. günde istatistiksel olarak önemli düzeyde düşük olduğu belirlendi (P<0.05). Plazma total antioksidan düzeylerinde gruplar arasında istatistiksel olarak bir farklılık gözlenmedi. Kalp dokusu total oksidan düzeylerinin 14. günde L-karnitin grubunun kontrol grubuna göre istatistiksel olarak daha düşük olduğu (P<0.001), Co-enzim Q10 grubunda ise istatistiksel olarak önemli bir fark olmadığı belirlendi. 28. günde deneme gruplarının kalp dokusu total oksidan düzeylerinin kontrol grubuna göre istatistiksel olarak düşük olduğu, bu düşüşün L-karnitin uygulanan grupta daha belirgin olduğu görüldü (P<0.001). Kalp dokusu total antioksidan düzeylerinde istatistiksel olarak bir farklılık tespit edilmedi. Sonuç olarak, L-karnitin ve Co-enzim Q10’nun hipertansiyonda kalbi ve damar sistemini serbest radikal hasarından koruyarak, oluşacak ikincil problemlerin şiddetini azaltabilecekleri kanaatine varıldı.

🔖

Cite This Article

Kamiloğlu, N. N. (2017). Effects of L-Carnitine and Co-enzyme Q10 Together with ACE Inhibitors on Total Oxidant and Antioxidant Levels in L-Name Hypertensive Rats. Veterinary Sciences and Practices, Cilt: 12 Sayı: 2, 143–151. https://ajindex.com/articles/917650

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Cohuet G., Struijker-Bouder H., 2006. Mechanism of target organ damage caused by hypertension:Therapeutic potential. Pharm Therap, 111, 81-98
  2. Yılmaz G., Aksulu HE., Demirel E., Ercan ZS., Zengil H., Türker RK., 1987. Modulation by endothelium of the vascular effects of angiotensin II. Agents Actions, 21, 184-190
  3. Rochette L., Lorin J., Zeller M., Guilland JC., Lorgis L., Cottin Y., Vergely C., 2013. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets?. Pharm Therap, 140, 239-257
  4. Landmesser U., Dikalov S., Price SR., McCann L., Fukai T., Holland SM., Mitch WE., Harrison DG., 2003. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest, 111, 1201-1209
  5. Magy L., Vincent F., Faure S., Messerli FH., Wang JG., Achard JM., Fournier A., 2005. The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des, 11, 3275-3291
  6. Arı UÇ., Kamiloğlu NN., 2015. Erkek sığırlarda ürogenital sistem anatomisi ve fizyolojisi. Türk Klin J Vet Sci-Surg- Special Topics, 1, 1-11
  7. Kurusaki R., Muramatsu Y., Kato H., Watanabe Y., Imai Y., Itoyama Y., Araki T., 2005. Effect of angiotensin-coverting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Europan Neuropsychopharmacology, 15, 57-67
  8. Lopez-Real A., Rey P., Soto-Otero R., Mendez- Alvarez E., Labandeira-Garcia JL., 2005. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6 hydroxydopamine rat model of Parkinsonism. J Neurosci Res, 81, 865-873
  9. Wright JT., Bakris G., Grene T., Agodoa LY., Apel LJ., Charleston J., Cheek D., Douglas-Baltimore JG., Gassman J., Glassock R., Hebert L., Jamerson K., Lewis J., Phillips RA., Toto RD., Middleton JP., Rostand SG., 2002. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc, 288, 2421-2431
  10. Taşar N., Şehirli Ö., Yiğiner Ö., Süleymanoğlu S., Yüksel M., Yeğen B., Şener G., 2012. Protective effects of Nigella sativa against hypertension-induced oxidative stress and cardiovascular dysfunction in rats. Marmara Pharmaceu J, 16, 141-149
  11. Hopkins RZ., 2016. Reactive Oxygen Species. Cell Med Press, 2, 290-297
  12. Halliwell B., Gutteridge JMC., 2015. Free radicals in biology and medicine, 15. Baskı, Oxford University Press, p